Compare HRB & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRB | XENE |
|---|---|---|
| Founded | 1955 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.2B |
| IPO Year | 1994 | 2014 |
| Metric | HRB | XENE |
|---|---|---|
| Price | $38.22 | $51.60 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $41.00 | ★ $68.55 |
| AVG Volume (30 Days) | ★ 2.5M | 1.2M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | ★ 6.55 | N/A |
| EPS | ★ 3.38 | N/A |
| Revenue | ★ $3,159,931,000.00 | $311,000.00 |
| Revenue This Year | $4.39 | N/A |
| Revenue Next Year | $3.21 | $2,496.48 |
| P/E Ratio | $11.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.16 | $30.00 |
| 52 Week High | $58.21 | $62.91 |
| Indicator | HRB | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 36.05 |
| Support Level | $29.24 | $39.93 |
| Resistance Level | $39.84 | $59.43 |
| Average True Range (ATR) | 1.36 | 1.60 |
| MACD | -0.26 | -0.23 |
| Stochastic Oscillator | 38.26 | 2.13 |
H&R Block Inc provides income tax return preparation services, digital do-it-yourself tax solutions, and other services related to income tax preparation to the general public in the United States, Canada, and Australia. The company mainly prepares tax returns for customers within the United States through its company-owned offices, franchise locations, and online tax software. The vast majority of H&R Block's offices are located in the U.S. The company derives the majority of its total revenue from the U.S. assisted tax preparation fees. Revenue from franchise and product royalties and digital do-it-yourself tax solutions is also relatively.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.